The SHIELD Study-silicosis

Status Recruiting

Clinical Trial Summary

An observational cohort study to derive biomarkers which are able to more accurately diagnose silicosis, as well as predict disease progression, assess response to treatment, and hasten therapeutic discovery.

Clinical Trial Description

Background: Silicosis is a fatal lung disease caused by inhaling silica particles. Australia is currently facing an epidemic with hundreds of young workers having contracted silicosis from machining engineered stone. AIMS: To establish the SHIELD COHORT and associated SHIELD BIOBANK to drive further discovery including assessing the efficacy of whole lung lavage for accelerated silicosis, uncovering disease biomarkers, and druggable targets. PARTICIPANTS: 75 participants who are respirable crystalline silica exposed workers, (this includes n=30 with silicosis, n=15 with progressive massive fibrosis and n=30 with no pneumoconiosis). METHODS: Advanced microscopy, 'omic platforms and single cell RNA sequencing. OUTCOME: The SHIELD study builds on the knowledge gap to accurately diagnose silicosis, as well as predict disease progression, assess response to treatment, and hasten therapeutic discovery ;

Study Design

Related Conditions & MeSH terms

Silicosis

Clinical Trial Details

NCT number	NCT05546944
Study type	Observational [Patient Registry]
Source	The University of Queensland
Contact	Daniel Chambers
Phone	(07) 3646 7498
Email	daniel.chambers@health.qld.gov.au
Status	Recruiting
Phase
Start date	August 16, 2022
Completion date	December 2024

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT01329003` - DNA-damage Pathways in Workers Exposed to Silica (Caesar Stone)	N/A
Not yet recruiting	`NCT01338064` - Oxidative Stress Biomarkers to Monitor and Early Detect Health Impairment in Workers Exposed to Silica (Caesar Stone)	N/A
Recruiting	`NCT04161014` - The Nintedanib in Progressive Pneumoconiosis Study (NiPPS): a Collaborative NSW Treatment Trial	Phase 2
Recruiting	`NCT05118256` - Pirfenidone for the Reduction of Metabolic, Inflammatory and Fibrogenic Activity in Complicated Silicosis	Phase 2
Completed	`NCT02430259` - Efficacy of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention	Phase 3
Recruiting	`NCT06403800` - Silicosis and Silicotuberculosis Among Small Scale Gemstone Miners in Northern Tanzania
Not yet recruiting	`NCT06011785` - Using Silica 12CH to Mitigate the Effects and Symptoms of Silicosis in Brazil	Early Phase 1
Not yet recruiting	`NCT05402176` - The SHIELD Whole Lung Lavage Study
Completed	`NCT02794701` - Comprehensive Risk Assessment of People With Silicosis: A Population-based Study
Completed	`NCT01977131` - Safety Study of Autologous Bone Marrow Stromal Cells With Modification by Hepatocyte Growth Factor to Treat Silicosis	Phase 1/Phase 2
Completed	`NCT00005280` - Specialized Center of Research in Occupational and Immunologic Lung Disease	N/A
Recruiting	`NCT05538299` - Silicosis Treatment, Action, Screening and Surveillance in Rwanda Trials
Completed	`NCT01725971` - Oscillation Mechanics of the Respiratory System in Never-smoking Patients With Silicosis	N/A
Recruiting	`NCT06090370` - Reducing Silica Exposure Among Brick Kiln Workers in Nepal	N/A
Completed	`NCT04205708` - Screening Strategy for Early Diagnosis of Silicosis in At-Risk Populations in Oklahoma